Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

• Market Cap: €184.54M
• Dividend Yield: N/A
• Average Volume (3M): 333.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: 14.18%
• EPS Growth: 72.73%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.32
• Shares Outstanding: 25,663,593
• 10 Day Avg. Volume: 370,302
• 30 Day Avg. Volume: 333,294
• PEG Ratio: 0.01
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 2.15
• P/FCF Ratio: -0.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): €37.10M

• Rating: 44 Neutral
• Price Target: kr7.00 ▲(3.70% Upside)

The overall stock score is primarily influenced by financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand for the company's laser therapy systems, suggesting successful market penetration and product adoption.

Gross Profit Margin

A high gross profit margin reflects effective cost management, allowing the company to maintain profitability at the gross level despite operational challenges.

Balance Sheet Health

Minimal leverage reduces financial risk, providing the company with greater flexibility to invest in growth opportunities and withstand economic fluctuations.

Negative Factors

Profitability Challenges

Negative profitability indicates that the company is struggling to convert revenue into profit, which could hinder long-term sustainability and growth potential.

Cash Flow Issues

Declining cash generation limits the company's ability to fund operations and invest in growth, potentially affecting future financial stability.

Return on Equity

Negative ROE suggests inefficiencies in generating returns for shareholders, which could impact investor confidence and the company's ability to raise capital.

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB Class B (CLS.B) is a Swedish medical technology company specializing in the development of innovative laser-based therapies for the treatment of cancer and other serious diseases. The company's core product offerings include advanced laser systems designed to provide precise and effective thermal therapy, enhancing treatment outcomes while minimizing damage to surrounding healthy tissues. CLS.B operates primarily within the healthcare sector, focusing on both clinical applications and partnerships with hospitals and medical professionals to integrate their laser technologies into standard treatment protocols.

How the Company Makes Money

CLS.B generates revenue through the sale of its laser therapy systems and related consumables to hospitals, clinics, and healthcare providers. The company also earns income through service agreements for maintenance and support of its equipment, as well as training programs for healthcare professionals to ensure effective use of their technologies. Additionally, CLS.B may engage in strategic partnerships with medical institutions and research organizations to conduct clinical trials and studies that validate the effectiveness of their products, potentially leading to increased sales and market penetration. These partnerships can also provide access to funding and resources, contributing to the company's overall financial performance.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Clinical Laserthermia Systems AB Class B shows promising revenue growth and a strong gross profit margin, but faces significant profitability challenges with negative net income and cash flow issues. The balance sheet is robust with low leverage, but the company struggles to generate returns on equity. Overall, while there are positive growth indicators, the company must address operational inefficiencies and improve cash flow management to enhance financial health.

Income Statement

The company shows a strong revenue growth rate of 18.57% in the TTM, indicating positive momentum. However, the net profit margin is significantly negative at -180.95%, and both EBIT and EBITDA margins are deeply negative, reflecting ongoing operational challenges and high costs relative to revenue. The gross profit margin is healthy at 73.99%, suggesting effective cost management at the gross level.

Balance Sheet

The balance sheet is stable with a very low debt-to-equity ratio of 0.0033, indicating minimal leverage and financial risk. However, the return on equity is negative at -63.84%, highlighting inefficiencies in generating returns for shareholders. The equity ratio is strong, suggesting a solid capital structure.

Cash Flow

The company has a negative free cash flow growth rate of -7.80% in the TTM, indicating declining cash generation. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.18, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.27M	18.78M	8.27M	6.27M	2.25M	1.33M
Gross Profit	14.28M	10.42M	3.00M	-2.79M	-3.63M	876.00K
EBITDA	-35.65M	-44.76M	-68.41M	-57.84M	-57.05M	-51.61M
Net Income	-38.38M	-47.62M	-79.79M	-70.66M	-63.62M	-57.94M
Balance Sheet
Total Assets	64.13M	78.56M	57.73M	49.51M	66.74M	44.40M
Cash, Cash Equivalents and Short-Term Investments	13.20M	22.51M	15.33M	10.59M	31.17M	11.87M
Total Debt	224.00K	224.00K	454.00K	30.68M	273.50K	673.50K
Total Liabilities	7.31M	12.88M	14.20M	41.64M	45.55M	30.47M
Stockholders Equity	59.56M	68.72M	45.77M	9.22M	21.79M	13.93M
Cash Flow
Free Cash Flow	-39.61M	-58.92M	-71.95M	-71.25M	-66.73M	-55.76M
Operating Cash Flow	-33.42M	-56.45M	-66.45M	-70.69M	-66.17M	-55.41M
Investing Cash Flow	-4.32M	-7.47M	-5.50M	-886.00K	-408.00K	-508.00K
Financing Cash Flow	35.35M	71.10M	76.69M	61.84M	85.88M	62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 6.75 is below the 20-day moving average (MA) of 7.99, below the 50-day MA of 8.19, and above the 200-day MA of 5.28, indicating a neutral trend. The MACD of -0.41 indicates Positive momentum. The RSI at 37.19 is Neutral, neither overbought nor oversold. The STOCH value of 26.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLS.B	44 Neutral	€184.54M	―	-63.39%	―	14.18%	72.73%
NOSA	43 Neutral	kr186.92M	-19.94	―	―	17.24%	35.77%
LXB	41 Neutral	€81.47M	―	-60.20%	―	163.12%	30.50%
SPEC	39 Underperform	kr69.27M	―	-50.21%	―	―	-108.64%
HEART	34 Underperform	kr136.96M	―	―	―	―	―